Cabaletta Bio, Inc. Common Stock (CABA) Stock Price

CABAStock
$3.12+108.00%52W
Market Cap$528.98M
P/E
PEG Ratio
Div yield
Beta3.46

CABA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-17.10%
Price vs S&P 500 (4W)14.44%
VGM Score57.96

CABA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.34-$0.34+0.76%(+$0.00)
Q1 2026-$0.39-$0.39-0.47%(-$0.00)
Q4 2025-$0.47-$0.40+14.12%(+$0.07)
Q3 2025-$0.46-$0.44+3.88%(+$0.02)
Q2 2025-$0.61-$0.73-19.35%(-$0.12)

CABA Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.19
4.19
4.19
4.19

Industry Peers — Biological Products(183)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
CABACabaletta Bio, Inc. Common Stock
C$3.12
AMGNAmgen IncCCB$432.42
GILDGilead Sciences IncCBB$145.68
ARGXargenx SE American Depositary SharesDAB$1023.21
MRNAModerna, Inc. Common StockDCA$137.99
RVMDRevolution Medicines, Inc. Common StockFA$207.88
BIIBBiogen Inc. Common StockCDB$218.50
BNTXBioNTech SE American Depositary ShareCCC$102.08
NBIXNeurocrine Biosciences IncCBC$154.06
EXELExelixis IncCBB$54.45
HALOHalozyme Therapeutics, Inc.CBB$105.35

About Cabaletta Bio, Inc. Common Stock

Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary CAART technology selectively eliminates disease-causing B cells while preserving normal B cells, offering the potential for deep and durable therapeutic effects. The company's CABA platform encompasses multiple strategies applicable across a broad range of autoimmune indications.